Article
Cell Biology
Xiaxia Niu, Ting Wu, Qishuang Yin, Xinsheng Gu, Gege Li, Changlong Zhou, Mei Ma, Li Su, Shu Tang, Yanan Tian, Ming Yang, Hongmei Cui
Summary: This study found that the PXR antagonist SPA70 can reduce resistance to paclitaxel in non-small cell lung cancer (NSCLC). The combination of PTX and SPA70 may be a potential novel treatment for taxane-resistant lung cancer.
Article
Medicine, General & Internal
Charles M. Rudin, Elisabeth Brambilla, Corinne Faivre-Finn, Julien Sage
Summary: Small-cell lung cancer is a type of lung cancer characterized by high proliferative rate, early metastasis, and poor prognosis, strongly associated with tobacco carcinogens. Most patients are diagnosed with metastatic disease, with only a small fraction having potentially curative earlier-stage disease. Genomic profiling reveals extensive chromosomal rearrangements and high mutation burden in SCLC, often involving inactivation of TP53 and RB1 tumor suppressor genes.
NATURE REVIEWS DISEASE PRIMERS
(2021)
Article
Biochemistry & Molecular Biology
Zhimin Tang, Yilan Zhang, Zhengyi Yu, Zhijun Luo
Summary: This study demonstrates that FOXO3a is involved in mediating the inhibitory effect of metformin on cancer stemness in PTX-resistant NSCLC cells, through the activation of AMPK and the inhibition of Akt and MAPK/MEK pathways.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
David E. Kozono, Thomas E. Stinchcombe, Joseph K. Salama, Jeffrey Bogart, W. Jeffrey Petty, Michael J. Guarino, Lyudmila Bazhenova, James M. Larner, Jared Weiss, Thomas A. DiPetrillo, Steven J. Feigenberg, Xin Chen, Zhaowen Sun, Silpa Nuthalapati, Lindsey Rosenwinkel, Eric F. Johnson, Bruce A. Bach, Yan Luo, Everett E. Vokes
Summary: This study evaluated the effects of veliparib in combination with chemoradiotherapy on patients with unresectable stage III NSCLC, demonstrating acceptable safety profile and antitumor activity with a median progression-free survival of 19.6 months.
Article
Medicine, General & Internal
Bob T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazieres, Misako Nagasaka, Lyudmila Bazhenova, Andreas N. Saltos, Enriqueta Felip, Jose M. Pacheco, Maurice Perol, Luis Paz-Ares, Kapil Saxena, Ryota Shiga, Yingkai Cheng, Suddhasatta Acharyya, Patrik Vitazka, Javad Shahidi, David Planchard, Pasi A. Janne
Summary: Trastuzumab deruxtecan demonstrated durable anticancer activity in previously treated HER2-mutant NSCLC patients, with two cases of fatal drug-related interstitial lung disease reported. The observed toxic effects were generally consistent with previous studies.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Helena Branco, Julio Oliveira, Catarina Antunes, Lucio L. Santos, Maria Helena Vasconcelos, Cristina P. R. Xavier
Summary: This study investigated the potential of using Pirfenidone to enhance the sensitivity of non-small cell lung cancer (NSCLC) cells to chemotherapy. The results showed that Pirfenidone increased the effectiveness of paclitaxel treatment on NSCLC cells without increasing toxicity in non-tumorigenic cells. This research suggests the possibility of repurposing Pirfenidone in combination with chemotherapy for treating NSCLC.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Medicine, General & Internal
Hajime Oi, Toshiaki Matsuda, Tomoki Kimura, Masahiro Morise, Yasuhiko Yamano, Toshiki Yokoyama, Kensuke Kataoka, Yasuhiro Kondoh
Summary: Weekly nab-PTX and PTX have similar efficacy and safety profiles for relapsed SCLC. In this retrospective study, there were no significant differences in response rate, median progression-free survival, and overall survival between the two treatment options.
Review
Oncology
Stephanie P. L. Saw, Boon-Hean Ong, Kevin L. M. Chua, Angela Takano, Daniel S. W. Tan
Summary: Despite the advancements in treatment for advanced non-small-cell lung cancer (NSCLC), there is a renewed interest in neoadjuvant strategies for early-stage NSCLC. These strategies, including targeted therapy and immunotherapy, have the potential to greatly impact survival outcomes for early-stage NSCLC patients.
Review
Oncology
Martin Reck, Jordi Remon, Matthew D. Hellmann
Summary: The past decade has seen significant progress in the treatment of metastatic non-small-cell lung cancer, with the development of specific antibodies leading to improved survival for many patients. Currently, nearly all mNSCLC patients receive PD-1 or PD-L1 therapy in the first-line setting, except those with targetable oncogenes.
JOURNAL OF CLINICAL ONCOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Meina Wang, Roy S. Herbst, Chris Boshoff
Summary: Over the past two decades, molecular targeted therapies and immunotherapies have significantly improved outcomes for non-small-cell lung cancer (NSCLC), but the majority of advanced NSCLCs eventually become resistant. The future challenge lies in the application of predictive biomarkers for patient stratification in order to better manage NSCLC.
Article
Oncology
Corey J. Langer, Ajeet Gajra, Cesare Gridelli, Kartik Konduri, Daniel Morgensztern, David Spigel, Denis Talbot, Michael Thomas, Jared Weiss, Richard Pilot, Rafia Bhore, Marianne Wolfsteiner, Teng Jin Ong, Mark Socinski
Summary: Despite the underrepresentation of certain patient populations in clinical trials for advanced NSCLC, a pooled analysis of elderly patients and those with renal impairment, diabetes, or poor performance status showed varying but promising outcomes, supporting the use of nab-paclitaxel-based regimens in these historically understudied and vulnerable populations.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Giuseppe Giaccone, Yongfeng He
Summary: Lung cancer is the leading cause of cancer related death, with two major histological subtypes, NSCLC and SCLC. Transformation from NSCLC to SCLC can cause treatment resistance, potentially due to therapy-induced changes or clonal selection. This article discusses the potential mechanisms, cell of origin, and genomic alterations in both de novo and transformed SCLC, as well as treatment options including chemotherapy, radiotherapy, TKIs, immunotherapy, and antiangiogenic agents.
SEMINARS IN CANCER BIOLOGY
(2023)
Review
Oncology
H. Adderley, F. H. Blackhall, C. R. Lindsay
Summary: Treatment stratification in stage IV NSCLC is guided by oncogene driver mutations, with a focus on small molecule therapy and immune checkpoint inhibitors. Proper sequencing of therapy is crucial for safe and effective treatment delivery.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2021)
Review
Oncology
Shenduo Li, Guilherme Sacchi de Camargo Correia, Jing Wang, Rami Manochakian, Yujie Zhao, Yanyan Lou
Summary: Lung cancer is the leading cause of cancer-related deaths globally, with non-small-cell lung cancer (NSCLC) being the most common type. Although targeted therapy has improved survival in NSCLC patients with actionable mutations, therapy resistance and lack of targeted agents for certain oncogenic driver mutations remain challenges. This review summarizes emerging targeted therapies that have been tested in first-in-human clinical trials in the past year.
Review
Biochemistry & Molecular Biology
Min Yuan, Yu Zhao, Hendrik-Tobias Arkenau, Tongnei Lao, Li Chu, Qing Xu
Summary: Small-cell lung cancer (SCLC) is a subtype of lung cancer characterized by high proliferation, early metastasis, and poor prognosis. Recent studies have identified extensive chromosomal rearrangements, high mutation burden, and loss-of-function mutations in tumor suppressor genes in SCLC. There are currently six potential treatable signaling pathways in SCLC. However, their role in SCLC tumor biology and cancer growth promotion is not well understood. Further research is needed to optimize drug targets, improve drug pharmacology, and identify potential biomarkers for novel therapies in SCLC.
SIGNAL TRANSDUCTION AND TARGETED THERAPY
(2022)
Article
Oncology
Si-Ho Kim, Cheol-In Kang, Soo-Hyun Lee, Joon-Sik Choi, Kyungmin Huh, Sun Young Cho, Doo Ryeon Chung, Hyo Jung Park, Soo-Youn Lee, Yae-Jean Kim, Kyong Ran Peck
Summary: A retrospective study was conducted to evaluate the clinical effectiveness of vancomycin loading strategy and factors associated with achieving optimal C-min. Patients were divided into loading (LD) and non-loading (NLD) groups, with no significant differences observed in achieving optimal C-min between the two groups before the third dose and within 72 hours. Risk factors for failing to achieve optimal C-min included higher creatinine clearance and serum albumin levels.
JOURNAL OF CHEMOTHERAPY
(2021)
Article
Chemistry, Analytical
Jongwon Oh, Min-Seung Park, Mi-Ryung Chun, Jung Hye Hwang, Jin-Young Lee, Jae Hwan Jee, Soo-Youn Lee
Summary: Measuring nicotine metabolites using liquid chromatography--tandem mass spectrometry is an objective method for identifying smoke exposure. The developed method for simultaneous measurement of multiple metabolites proved to be sensitive and effective in screening smoking status in the general population.
JOURNAL OF ANALYTICAL TOXICOLOGY
(2022)
Article
Medicine, Research & Experimental
Hye In Woo, Jisook Park, Shinn-Won Lim, Doh Kwan Kim, Soo-Youn Lee
Summary: Proteomic analysis revealed changes in transthyretin and TBG levels in MDD patients, which also changed after antidepressant treatment.
JOURNAL OF TRANSLATIONAL MEDICINE
(2021)
Article
Multidisciplinary Sciences
Hee Young Ju, Ji Won Lee, Hee Won Cho, Ju Kyung Hyun, Youngeun Ma, Eun Sang Yi, Keon Hee Yoo, Ki Woong Sung, Rihwa Choi, Hong Hoe Koo, Soo-Youn Lee
Summary: The study found that patients with NUDT15 variants showed similar DNA-TGN concentrations even at low doses of 6MP and exhibited high variability in DNA-TGN levels. Additionally, DNA-TGN concentration did not show a significant correlation with WBC count.
Article
Medicine, Research & Experimental
Eunsol Yang, Hyejung Choi, Jin-Sol Park, Young-Woock Noh, Chi-Min Choi, Woo-Jong Lee, Jae-Wook Ko, Jungryul Kim
Summary: KMRC011 is a novel Toll-like receptor 5 agonist being developed for the treatment of acute radiation syndrome (ARS). A first-in-human study investigated the tolerability, pharmacokinetics, and pharmacodynamics of a single intramuscular dose of KMRC011 in healthy subjects. Doses ranging from 5 to 15 μg of KMRC011 were well tolerated and showed TLR5 agonist-like activities by increasing serum G-CSF, IL-6, and absolute neutrophil counts.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE
(2021)
Article
Chemistry, Medicinal
Changhee Ha, Hyun-Seung Lee, Eun Yeon Joo, Young-Min Shon, Seung Bong Hong, Dae-Won Seo, Soo-Youn Lee
Summary: The study investigated the therapeutic drug monitoring of Levetiracetam in Korean epilepsy patients, revealing a large inter-individual difference in its pharmacokinetics and its susceptibility to EIAEDs. There was a strong correlation between weight-adjusted Levetiracetam dosage and concentrations.
Article
Gastroenterology & Hepatology
Eun Sil Kim, Sujin Choi, So Yoon Choi, Ji Hyung Park, Byung-Ho Choe, Soo-Youn Lee, Mi Jin Kim, Yon Ho Choe, Ben Kang
Summary: NUDT15 intermediate metabolisers are associated with lower loss of response in pediatric patients with CD treated with IFX and AZA combination therapy.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Medicine, General & Internal
Sang-Mi Kim, Hyun-Seung Lee, Min-Ji Kim, Hyung-Doo Park, Soo-Youn Lee
Summary: The study evaluated the diagnostic value of nine serum biomarkers for vancomycin-induced kidney injury (VIKI) and found that TFF3, cystatin C, TNF-R1, and osteopontin had excellent diagnostic value for VIKI and showed a strong negative correlation with estimated glomerular filtration rate.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Oncology
E. H. Cho, J. -Y. Kim, S. -A. Im, K. H. Jung, J. Sohn, K. S. Lee, Y. S. Chae, K. H. Lee, J. H. Kim, J. -H. Jang, J. H. Ahn, M. S. Park, S. -Y. Lee, Y. H. Park
Summary: In this study, genetic polymorphisms of rs1044457 in CMPK1, rs693955 in SLC29A1, and rs2807312 in TLE4 were found to be significantly associated with 6-month progression-free survival (PFS) rate and/or PFS duration in breast cancer patients. Further studies with a larger sample size and expression study would be helpful to validate the association of genetic polymorphisms and the clinical efficacy of gemcitabine.
Editorial Material
Medical Laboratory Technology
Young Jin Kim, Soo-Youn Lee, Mina Hur
ANNALS OF LABORATORY MEDICINE
(2022)
Correction
Medicine, General & Internal
Sang-Mi Kim, Hyun-Seung Lee, Min-Ji Kim, Hyung-Doo Park, Soo-Youn Lee
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medical Laboratory Technology
Beomki Lee, Won Young Heo, Jee Ah Kim, Hyun Seung Lee, Narae Hwang, Hyung-Doo Park, Se In Sung, Yun Sil Chang, Won Soon Park, Soo-Youn Lee
Summary: The NeoBase 2 assay was comprehensively evaluated and found to be able to distinguish between transient tyrosinemia of the newborn (TTN) and tyrosinemia type 1 (TYR 1) using succinylacetone (SUAC). Different cutoffs were established for analytes in preterm neonates. Simultaneous measurement of tyrosine (Tyr) and SUAC successfully differentiated between TYR 1 and TTN.
ANNALS OF LABORATORY MEDICINE
(2023)
Article
Biochemistry & Molecular Biology
Young-Gon Kim, Jisook Park, Eun Young Park, Sang-Mi Kim, Soo-Youn Lee
Summary: This study investigated the response of normal pancreatic islet cells to pancreatic cancer-derived exosomes in order to identify potential biomarkers for pancreatic cancer-induced diabetes mellitus (PC-DM) and pancreatic cancer itself. Changes in microRNA expression were evaluated, and 24 candidate miRNA markers were proposed. These markers showed relevance to diabetes mellitus and/or insulin resistance, suggesting a potential association with PC-DM.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Urology & Nephrology
Beomki Lee, Soo-Youn Lee, Deok Hyun Han, Hyung-Doo Park
Summary: Cystinuria is a genetic disorder caused by defects in the b(0,+) transporter system. Variants in SLC3A1 and SLC7A9 follow different inheritance patterns and complicate variant interpretation. This study identified novel variants and used in silico analysis to predict functional loss and protein expression changes.
Review
Medicine, General & Internal
Joon-sik Choi, Seo Hee Yoon, Hyo Jung Park, Soo-Youn Lee, Yae-Jean Kim
Summary: There is insufficient evidence on teicoplanin trough levels in pediatric populations, but favorable clinical efficacy can be achieved in the majority of patients using recommended dosing regimens.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)